A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

References

• Gao P, Mei C, He L, et al. Designing multifunctional cancer-targeted nanosystem for magnetic resonance molecular imaging-guided theranostics of lung cancer. Drug Deliv. 2018;25:1811–1825.
   PubMed Web of Science ®Google Scholar
• Kovacs N, Szigeti K, Hegedus N, et al. Multimodal PET/MRI imaging results enable monitoring the side effects of radiation therapy. Contrast Media Mol Imaging. 2018;2018:5906471.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhen M, Guan M, et al. Amino acid modified [70] fullerene derivatives with high radical scavenging activity as promising bodyguards for chemotherapy protection. Sci Rep. 2018;8:16573.
   PubMed Web of Science ®Google Scholar
• Movahedi MM, Mehdizadeh A, Koosha F, et al. Investigating the photo-thermo-radiosensitization effects of folate-conjugated gold nanorods on KB nasopharyngeal carcinoma cells. Photodiagnosis Photodyn Ther. 2018;24:324–331.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2018;139:395–411.
   PubMed Web of Science ®Google Scholar
• Wang X, Ouyang X, Chen J, et al. Nanoparticulate photosensitizer decorated with hyaluronic acid for photodynamic/photothermal cancer targeting therapy. Nanomedicine (Lond). 2018;14:151–167.
   PubMed Web of Science ®Google Scholar
• Warda W, Larosa F, Neto Da Rocha M, et al. CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells. Cancer Res. 2018;79:663–675.
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang F, Liu Q, et al. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. Invest New Drugs. 2018.
   Web of Science ®Google Scholar
• Xu L, Wan C, Du J, et al. Synthesis, characterization, and in vitro evaluation of targeted gold nanoshelled poly(d,l-lactide-co-glycolide) nanoparticles carrying anti p53 antibody as a theranostic agent for ultrasound contrast imaging and photothermal therapy. J Biomater Sci Polym Ed. 2017;28:415–430.
   PubMed Web of Science ®Google Scholar
• Koczera P, Appold L, Shi Y, et al. PBCA-based polymeric microbubbles for molecular imaging and drug delivery. J Control Release. 2017;259:128–135.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Redman MW, Kim ES, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018;19:101–114.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–730.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628.
   PubMed Web of Science ®Google Scholar
• Khoshtinat Nikkhoi S, Rahbarizadeh F, Ahmadvand D, et al. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: in vitro proof-of-concept. Eur J Pharm Sci. 2018;122:42–50.
   PubMed Web of Science ®Google Scholar
• He XX, Du S, Gao SQ, et al. Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells. J Cell Mol Med. 2018;22:3259–3263.
   PubMed Web of Science ®Google Scholar
• Hirasawa S, Kitahara Y, Okamatsu Y, et al. Facile and efficient chemoenzymatic semisynthesis of Fc-fusion compounds for half-life extension of pharmaceutical components. Bioconjug Chem. 2019.
   PubMed Web of Science ®Google Scholar
• Shi S, Hong H, Orbay H, et al. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015;42:1295–1303.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kobayashi N, Zettlitz KA, et al. Near-infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin Cancer Res. 2019;25:188–200.
   PubMed Web of Science ®Google Scholar
• Leoh LS, Kim YK, Candelaria PV, et al. Efficacy and mechanism of antitumor activity of an antibody targeting transferrin receptor 1 in mouse models of human multiple myeloma. JI. 2018;200:3485–3494.
   Google Scholar
• Xin L, Cao J-Q, Liu C, et al. Evaluation of rMETase-loaded stealth PLGA/liposomes modified with anti-CAGE scFV for treatment of gastric carcinoma. J Biomed Nanotechnol. 2015;11:1153–1161.
   PubMed Web of Science ®Google Scholar
• Min HS, Kim HJ, Ahn J, et al. Tuned density of anti-tissue factor antibody fragment onto siRNA-loaded polyion complex micelles for optimizing targetability into pancreatic cancer cells. Biomacromolecules. 2018;19:2320–2329.
   PubMed Web of Science ®Google Scholar
• Xing J, Lin L, Li J, et al. BiHC, a T-cell-engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells. Transl Oncol. 2017;10:780–785.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo J, Zhang XL, et al. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. Int J Pharm. 2015;496:1026–1033.
   PubMed Web of Science ®Google Scholar
• Razzaqi M, Rasaee MJ, Paknejad M. A critical challenge in the development of antibody: selecting the appropriate fragment of the target protein as an antigen based on various epitopes or similar structure. Mol Immunol. 2019;111:128–135.
   PubMed Web of Science ®Google Scholar
• Benschop RJ, Chow CK, Tian Y, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019;11:1175.
   PubMed Web of Science ®Google Scholar
• Zettlitz KA, Tavare R, Tsai WK, et al. 18)F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. Eur J Nucl Med Mol Imaging. 2019;46:489–500.
   PubMed Web of Science ®Google Scholar
• Wingler LM, McMahon C, Staus DP, et al. Distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody. Cell. 2019;176:479–490.e12.
   PubMed Web of Science ®Google Scholar
• Li C, Wang Y, Liu T, et al. An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. Antiviral Res. 2019;162:118–129.
   PubMed Web of Science ®Google Scholar
• Xavier S, Gopi Mohan C, Nair S, et al. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation. Int J Biol Macromol. 2019;124:17–24.
   PubMed Web of Science ®Google Scholar
• Lv J, Zhao R, Wu D, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12:6380000.
   Web of Science ®Google Scholar
• Groof Twm D, Mashayekhi V, Fan TS, et al. Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells. Mol Pharm. 2019;16:3145–3156.
   PubMed Web of Science ®Google Scholar
• Li T, Vandesquille M, Koukouli F, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1–10.
   PubMed Web of Science ®Google Scholar
• Vandesquille M, Li T, Po C, et al. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease. MAbs. 2017;9:1016–1027.
   PubMed Web of Science ®Google Scholar
• Volz J, Mammadova-Bach E, Gil-Pulido J, et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. 2019;133:2696–2706.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhao W, Bai X, et al. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates. Eur J Pharm Sci. 2019;134:81–92.
   PubMed Web of Science ®Google Scholar
• Beha N, Harder M, Ring S, et al. IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands in the single-chain format for cancer immunotherapy. Mol Cancer Ther. 2019;18:1278.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu N, Fan K, et al. A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions. Mol Immunol. 2019;109:149–156.
   PubMed Web of Science ®Google Scholar
• Iizuka A, Nonomura C, Ashizawa T, et al. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv antibody targets human breast cancer. Clin Cancer Res. 2019;25:2925–2934.
   PubMed Web of Science ®Google Scholar
• Kapelski S, Cleiren E, Attar RM, et al. Influence of the bispecific antibody IgG subclass on T cell redirection. MAbs. 2019;26:1–13.
   Google Scholar
• Crawford A, Haber L, Kelly MP, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019;11:eaau7534.
   PubMed Web of Science ®Google Scholar
• Haylock AK, Spiegelberg D, Mortensen AC, et al. Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. Int J Oncol. 2016;48:461–470.
   PubMed Web of Science ®Google Scholar
• El-Sayed A, Bernhard W, Barreto K, et al. Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts. Theranostics. 2018;8:4856–4869.
   PubMed Web of Science ®Google Scholar
• Alric C, Herve-Aubert K, Aubrey N, et al. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes. J Nanobiotechnol. 2018;16:18.
   PubMed Web of Science ®Google Scholar
• Ueda M, Hisada H, Temma T, et al. Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression. Mol Imaging Biol. 2015;17:102–110.
   PubMed Web of Science ®Google Scholar
• Tsai WK, Zettlitz KA, Tavare R, et al. Dual-modality immunoPET/fluorescence imaging of prostate cancer with an anti-PSCA Cys-minibody. Theranostics. 2018;8:5903–5914.
   PubMed Web of Science ®Google Scholar
• Boogerd LSF, Boonstra MC, Prevoo H, et al. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: preclinical validation. Surg Oncol. 2019;28:1–8.
   PubMed Web of Science ®Google Scholar
• Knowles SM, Tavare R, Zettlitz KA, et al. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res. 2014;20:6367–6378.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kobayashi N, Zettlitz KA, et al. Near-infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin Cancer Res. 2019;25:188–200.
   PubMed Web of Science ®Google Scholar
• Solomon VR, Gonzalez C, Alizadeh E, et al. Tc(CO)3(+) labeled domain I/II-specific anti-EGFR (scFv)2 antibody fragment for imaging EGFR expression. Eur J Med Chem. 2018;157:437–446.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan G, McDougald D, Choi J, et al. Preclinical evaluation of 18F-labeled Anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET. J Nucl Med. 2016;57:967–973.
   PubMed Web of Science ®Google Scholar
• Gao Y, Hernandez C, Yuan HX, et al. Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents. Nanomedicine. 2017;13:2159–2168.
   PubMed Web of Science ®Google Scholar
• Long NE, Sullivan BJ, Ding H, et al. Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging. J Biol Chem. 2018;293:9030–9040.
   PubMed Web of Science ®Google Scholar
• Rios X, Compte M, Gomez-Vallejo V, et al. Immuno-PET imaging and pharmacokinetics of an anti-CEA scFv-based trimerbody and its monomeric counterpart in human gastric carcinoma-bearing mice. Mol Pharmaceutics. 2019;16:1025–1035.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu C, Hu F, et al. PET imaging of VCAM-1 expression and monitoring therapy response in tumor with a (68)Ga-labeled single chain variable fragment. Mol Pharmaceutics. 2018;15:609–618.
   PubMed Web of Science ®Google Scholar
• Zhou Z, McDougald D, Devoogdt N, et al. Labeling single domain antibody fragments with fluorine-18 using 2,3,5,6-tetrafluorophenyl 6-[(18)F]fluoronicotinate resulting in high tumor-to-kidney ratios. Mol Pharmaceutics. 2019;16:214–226.
   PubMed Web of Science ®Google Scholar
• Zettlitz KA, Tsai WK, Knowles SM, et al. [(89)Zr]A2cDb immuno-PET of prostate cancer in a human prostate stem cell antigen knock-in (hPSCA KI) syngeneic model. Mol Imaging Biol. 2019;
   PubMed Web of Science ®Google Scholar
• Uehara T, Yokoyama M, Suzuki H, et al. A Gallium-67/68-labeled antibody fragment for immuno-SPECT/PET shows low renal radioactivity without loss of tumor uptake. Clin Cancer Res. 2018;24:3309–3316.
   PubMed Web of Science ®Google Scholar
• Chen F, Ma K, Madajewski B, et al. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun. 2018;9:4141.
   PubMed Web of Science ®Google Scholar
• Bauerschlag D, Meinhold-Heerlein I, Maass N, et al. Detection and specific elimination of EGFR(+) ovarian cancer cells using a near infrared photoimmunotheranostic approach. Pharm Res. 2017;34:696–703.
   PubMed Web of Science ®Google Scholar
• Yuan X, Yang M, Chen X, et al. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunol Immunother. 2017;66:367–378.
   PubMed Web of Science ®Google Scholar
• Mazzocco C, Fracasso G, Germain-Genevois C, et al. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Sci Rep. 2016;6:23314.
   PubMed Web of Science ®Google Scholar
• Boonstra MC, Tolner B, Schaafsma BE, et al. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. Int J Cancer. 2015;137:1910–1920.
   PubMed Web of Science ®Google Scholar
• Sonn GA, Behesnilian AS, Jiang ZK, et al. Fluorescent image-guided surgery with an anti-prostate stem cell antigen (PSCA) diabody enables targeted resection of mouse prostate cancer xenografts in real time. Clin Cancer Res. 2016;22:1403–1412.
   PubMed Web of Science ®Google Scholar
• Zettlitz KA, Waldmann CM, Tsai WK, et al. A dual-modality linker enables site-specific conjugation of antibody fragments for (18)F-immunoPET and fluorescence imaging. J Nucl Med. 2019.
   PubMed Web of Science ®Google Scholar
• Luo H, Hernandez R, Hong H, et al. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci USA. 2015;112:12806–12811.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang XY, Chen YL, et al. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy. Acta Biomater. 2018;80:308–326.
   PubMed Web of Science ®Google Scholar
• Luo H, England CG, Goel S, et al. ImmunoPET and near-infrared fluorescence imaging of pancreatic cancer with a dual-labeled bispecific antibody fragment. Mol Pharmaceutics. 2017;14:1646–1655.
   PubMed Web of Science ®Google Scholar
• Hernot S, Unnikrishnan S, Du Z, et al. Nanobody-coupled microbubbles as novel molecular tracer. J Control Release. 2012;158:346–353.
   PubMed Web of Science ®Google Scholar
• Fan X, Wang L, Guo Y, et al. Ultrasonic nanobubbles carrying anti-PSMA nanobody: construction and application in prostate cancer-targeted imaging. PLoS One. 2015;10:e0127419.
   PubMed Web of Science ®Google Scholar
• Kanazaki K, Sano K, Makino A, et al. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging. Nanomedicine. 2015;11:2051–2060.
   PubMed Web of Science ®Google Scholar
• Lei G, Xu M, Xu Z, et al. A novel fully human agonistic single chain fragment variable antibody targeting death receptor 5 with potent antitumor activity in vitro and in vivo. Int J Mol Sci. 2017;18:2064.
   PubMed Web of Science ®Google Scholar
• Rabenhold M, Steiniger F, Fahr A, et al. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously. J Control Release. 2015;201:56–67.
   PubMed Web of Science ®Google Scholar
• Yang W, Hu Q, Xu Y, et al. Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C Mater Biol Appl. 2018;89:328–335.
   PubMed Web of Science ®Google Scholar
• Kim M, Pyo S, Kang CH, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One. 2018;13:e0198347.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–856.
   PubMed Web of Science ®Google Scholar
• Pearce AK, Fuchs AV, Fletcher NL, et al. Targeting nanomedicines to prostate cancer: evaluation of specificity of ligands to two different receptors in vivo. Pharm Res. 2016;33:2388–2399.
   PubMed Web of Science ®Google Scholar
• Ji X, Shen Y, Sun H, et al. A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel. Tumor Biol. 2016;37:10085–10096.
   PubMedGoogle Scholar
• Lee D, Kim D, Choi YB, et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs. 2016;8:892–904.
   PubMed Web of Science ®Google Scholar
• Ahn HM, Ryu J, Song JM, et al. Anti-cancer activity of novel TM4SF5-targeting antibodies through TM4SF5 neutralization and immune cell-mediated cytotoxicity. Theranostics. 2017;7:594–613.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang Y, Zhang M, et al. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget. 2016;7:23594–23607.
   PubMedGoogle Scholar
• Sokolova E, Proshkina G, Kutova O, et al. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo. J Control Release. 2016;233:48–56.
   PubMed Web of Science ®Google Scholar
• Amoury M, Kolberg K, Pham AT, et al. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Lett. 2016;372:201–209.
   PubMed Web of Science ®Google Scholar
• Lv X, Zhang J, Xu R, et al. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells. Appl Microbiol Biotechnol. 2016;100:6403–6413.
   PubMed Web of Science ®Google Scholar
• Aubrey N, Allard-Vannier E, Martin C, et al. Site-specific conjugation of Auristatins onto engineered scFv using second generation maleimide to target HER2-positive breast cancer in vitro. Bioconjugate Chem. 2018;29:3516–3521.
   PubMed Web of Science ®Google Scholar
• Tang J, Howard CB, Mahler SM, et al. Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. Nanoscale. 2018;10:4258–4266.
   PubMed Web of Science ®Google Scholar
• Hou SC, Chen HS, Lin HW, et al. High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries. Sci Rep. 2016;6:31878.
   PubMed Web of Science ®Google Scholar
• Amoury M, Mladenov R, Nachreiner T, et al. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein. Int J Cancer. 2016;139:916–927.
   PubMed Web of Science ®Google Scholar
• Dou S, Yang XZ, Xiong MH, et al. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2(+) breast cancer. Adv Healthcare Mater. 2014;3:1792–1803.
   Web of Science ®Google Scholar
• Su Y, Yu L, Liu N, et al. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Cancer Lett. 2013;338:282–291.
   PubMed Web of Science ®Google Scholar
• Jiang K, Li J, Yin J, et al. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials. 2015;59:77–87.
   PubMed Web of Science ®Google Scholar
• Kaplan G, Mazor R, Lee F, et al. Improving the in vivo efficacy of an Anti-Tac (CD25) immunotoxin by pseudomonas exotoxin A domain II engineering. Mol Cancer Ther. 2018;17:1486–1493.
   PubMed Web of Science ®Google Scholar
• Geddie ML, Kohli N, Kirpotin DB, et al. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2017;9:58–67.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen Y, Li J, et al. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Cancer Sci. 2017;108:1493–1503.
   PubMed Web of Science ®Google Scholar
• Herve-Aubert K, Allard-Vannier E, Joubert N, et al. Impact of site-specific conjugation of ScFv to multifunctional nanomedicines using second generation maleimide. Bioconjugate Chem. 2018;29:1553–1559.
   PubMed Web of Science ®Google Scholar
• Niwa T, Kasuya Y, Suzuki Y, et al. Novel immunoliposome technology for enhancing the activity of the agonistic antibody against the tumor necrosis factor receptor superfamily. Mol Pharmaceutics. 2018;15:3729–3740.
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Dhokai S, Tsikudo EG, et al. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models. Eur J Pharm Biopharm. 2016;108:54–67.
   PubMed Web of Science ®Google Scholar
• Chang, T M S.ARTIFICIAL CELL evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):997–1013. doi:10.1080/21691401.2019.1577885.
   PubMed Web of Science ®Google Scholar
• Li T, Amari T, Semba K, et al. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Nanomedicine. 2017;13:1219–1227.
   PubMed Web of Science ®Google Scholar
• Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9:5150.
   PubMed Web of Science ®Google Scholar
• Libutti SK, Tamarkin L, Nilubol N. Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. Oncotarget. 2018;9:35723–35725.
   PubMedGoogle Scholar
• Miyazaki T, Ikeda K, Sato W, et al. Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression. Oncogenesis. 2018;7:7.
   PubMed Web of Science ®Google Scholar
• Riley, R S, June, C H, Langer, R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z.
   PubMed Web of Science ®Google Scholar
• Jiang H, Shi Z, Wang P, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111:409–418.
   PubMedGoogle Scholar
• de Bruin RCG, Veluchamy JP, Lougheed SM, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vgamma9Vdelta2-T cells. Oncoimmunology. 2018;7:e1375641.
   Web of Science ®Google Scholar
• Zhang C, Oberoi P, Oelsner S, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.
   PubMed Web of Science ®Google Scholar
• Harwood SL, Alvarez-Cienfuegos A, Nunez-Prado N, et al. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology. 2018;7:e1377874.
   PubMed Web of Science ®Google Scholar
• Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol Res. 2018;6:776–787.
   PubMed Web of Science ®Google Scholar
• Satta A, Mezzanzanica D, Caroli F, et al. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs. 2018;10:1084–1097.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheng M, Cheung IY, et al. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. Oncoimmunology. 2015;4:e989776.
   PubMed Web of Science ®Google Scholar
• Krenciute G, Krebs S, Torres D, et al. Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T cells to IL13Ralpha2-positive glioma. Mol Ther. 2016;24:354–363.
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Berahovich R, Zhou H, et al. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers (Basel). 2017;9:139.
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20:1287–1294.
   PubMed Web of Science ®Google Scholar
• Rius Ruiz I, Vicario R, Morancho B, et al. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci Transl Med. 2018;10:eaat1445.
   PubMed Web of Science ®Google Scholar